CL2021000282A1 - Inhibidores de ckd8/19 - Google Patents

Inhibidores de ckd8/19

Info

Publication number
CL2021000282A1
CL2021000282A1 CL2021000282A CL2021000282A CL2021000282A1 CL 2021000282 A1 CL2021000282 A1 CL 2021000282A1 CL 2021000282 A CL2021000282 A CL 2021000282A CL 2021000282 A CL2021000282 A CL 2021000282A CL 2021000282 A1 CL2021000282 A1 CL 2021000282A1
Authority
CL
Chile
Prior art keywords
inhibitors
ckd8
compounds
cdk8
disorders
Prior art date
Application number
CL2021000282A
Other languages
English (en)
Inventor
Dmitry Valentinovich Morozov
Pavel Andreevich Iakovlev
Mariia Andreevna Kasatkina
Elena Aleksandrovna Maksimenko
Aleksei Leonidovich Mindich
Anna Jur'evna Chestnova
Andrei Ivanovich Alafinov
Aleksei Sergeevich Gavrilov
Anton Aleksandrovich Evdokimov
Liliana Vyacheslavovna Lenshmidt
Mariia Sergeevna Mishina
Sergei Aleksandrovich Silonov
Evgenii Jur'evich Smirnov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CL2021000282A1 publication Critical patent/CL2021000282A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de la fórmula I: que tienen las propiedades de los inhibidores de la CDK8/19; a composiciones farmacéuticas que comprenden dichos compuestos; y al uso de estos como medicamento para tratar enfermedades y trastornos.
CL2021000282A 2018-08-03 2021-02-02 Inhibidores de ckd8/19 CL2021000282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19

Publications (1)

Publication Number Publication Date
CL2021000282A1 true CL2021000282A1 (es) 2021-08-13

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000282A CL2021000282A1 (es) 2018-08-03 2021-02-02 Inhibidores de ckd8/19

Country Status (19)

Country Link
US (1) US11840531B2 (es)
EP (1) EP3831829A4 (es)
JP (1) JP7365396B2 (es)
KR (1) KR20210040416A (es)
CN (1) CN113166140B (es)
AR (1) AR115898A1 (es)
AU (1) AU2019313199B2 (es)
BR (1) BR112021001939A2 (es)
CA (1) CA3108298A1 (es)
CL (1) CL2021000282A1 (es)
CO (1) CO2021001174A2 (es)
EA (1) EA202190452A1 (es)
MA (1) MA52375B2 (es)
MX (1) MX2021001335A (es)
PE (1) PE20210416A1 (es)
PH (1) PH12021550258A1 (es)
RU (1) RU2761824C2 (es)
TW (1) TWI839374B (es)
WO (1) WO2020027704A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CN101939312A (zh) * 2007-12-06 2011-01-05 先灵公司 γ分泌酶调节剂
CA2813708C (en) * 2010-10-18 2019-09-17 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
CN106817900A (zh) * 2014-07-17 2017-06-09 默克专利有限公司 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
JP7027343B2 (ja) * 2016-05-23 2022-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄｋ８／ｃｄｋ１９阻害剤としての新しいフェニルピラゾリルアセトアミド化合物及び誘導体

Also Published As

Publication number Publication date
AU2019313199A1 (en) 2021-03-11
CO2021001174A2 (es) 2021-02-26
RU2018128415A3 (es) 2021-03-30
CN113166140A (zh) 2021-07-23
WO2020027704A1 (ru) 2020-02-06
US20210246138A1 (en) 2021-08-12
PH12021550258A1 (en) 2021-10-11
EA202190452A1 (ru) 2021-04-13
MA52375B2 (fr) 2023-02-28
JP7365396B2 (ja) 2023-10-19
MX2021001335A (es) 2021-04-12
PE20210416A1 (es) 2021-03-04
CA3108298A1 (en) 2020-02-06
CN113166140B (zh) 2024-06-14
MA52375A1 (fr) 2021-12-31
BR112021001939A2 (pt) 2021-04-27
TWI839374B (zh) 2024-04-21
RU2761824C2 (ru) 2021-12-13
JP2021533143A (ja) 2021-12-02
EP3831829A1 (en) 2021-06-09
RU2018128415A (ru) 2020-02-04
US11840531B2 (en) 2023-12-12
KR20210040416A (ko) 2021-04-13
AU2019313199B2 (en) 2023-07-06
TW202012406A (zh) 2020-04-01
AR115898A1 (es) 2021-03-10
EP3831829A4 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
MX2015009591A (es) Amidas como moduladores de canales de sodio.
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2021004566A (es) Compuestos terapeuticos.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CR20150184A (es) Derivados de n-(2-aminacíclica)etil)benzamida como inhibidores de p2x7
CL2021000282A1 (es) Inhibidores de ckd8/19
UY38133A (es) Nuevos inhibidores de cdk8/19
CL2017002229A1 (es) Inhibidores de bace1.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
CL2017001602A1 (es) Derivados de fumagilol.
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
UY31989A (es) Nuevos derivados